Drug Pipeline

Mezigdomide Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
12
Active Studies
8
Recruiting
2
Phase 3
9
Top Sponsors
2
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-05-14 NCT05981209
Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory…
overall status: "Recruiting" → "Active Not Recruiting"
2026-05-14 NCT05981209
Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory…
Enrollment reduced: 27 -> 12 participants
Active Studies by Phase
Phase 3
2
Phase 2
1
Phase 1/2
3
Phase 1
6
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT05519085 A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus… Relapsed or Refractory Multiple Myeloma Recruiting
NCT05552976 A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone… Relapsed or Refractory Multiple Myeloma Active, Not Recruiting
Phase 2
NCT06627751 Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory… Extramedullary Disease in Multiple Myeloma Recruiting
Phase 1/2
NCT07356154 A Study of Revumenib and Mezigdomide in People With Leukemia Leukemia Recruiting
NCT06988488 A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and… Multiple Myeloma Recruiting
NCT02343042 Selinexor and Backbone Treatments of Multiple Myeloma Patients Multiple Myeloma Active, Not Recruiting
Phase 1
NCT07105059 A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma Multiple Myeloma Recruiting
NCT06121843 A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene… Multiple Myeloma Recruiting
NCT06048250 Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed… Multiple Myeloma Recruiting
NCT07032714 Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma Relapsed Refractory Multiple Myeloma (RRMM) Recruiting
NCT07355335 Ziftomenib + Mezigdomide in Adolesc. and Adults w/ R/R AML KMT2A-rearranged Not Yet Recruiting
NCT05981209 Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory… Recurrent Multiple Myeloma Active, Not Recruiting
Sponsors Running Mezigdomide Trials
Disease Areas
Get alerts when Mezigdomide trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free